Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors
We performed a case-control genome-wide association study (GWAS) to identify single nucleotide polymorphisms (SNPs) associated with musculoskeletal adverse events (MS-AEs) in women treated with aromatase inhibitors (AIs) for early breast cancer. A nested case-control design was used to select patien...
Uložené v:
| Vydané v: | Journal of clinical oncology Ročník 28; číslo 31; s. 4674 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
01.11.2010
|
| Predmet: | |
| ISSN: | 1527-7755, 1527-7755 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | We performed a case-control genome-wide association study (GWAS) to identify single nucleotide polymorphisms (SNPs) associated with musculoskeletal adverse events (MS-AEs) in women treated with aromatase inhibitors (AIs) for early breast cancer.
A nested case-control design was used to select patients enrolled onto the MA.27 phase III trial comparing anastrozole with exemestane. Cases were matched to two controls and were defined as patients with grade 3 or 4 MS-AEs (according to the National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0) or those who discontinued treatment for any grade of MS-AE within the first 2 years. Genotyping was performed with the Illumina Human610-Quad BeadChip.
The GWAS included 293 cases and 585 controls. A total of 551,358 SNPs were analyzed, followed by imputation and fine mapping of a region of interest on chromosome 14. Four SNPs on chromosome 14 had the lowest P values (2.23E-06 to 6.67E-07). T-cell leukemia 1A (TCL1A) was the gene closest (926-7000 bp) to the four SNPs. Functional genomic studies revealed that one of these SNPs (rs11849538) created an estrogen response element and that TCL1A expression was estrogen dependent, was associated with the variant SNP genotypes in estradiol-treated lymphoblastoid cells transfected with estrogen receptor alpha and was directly related to interleukin 17 receptor A (IL17RA) expression.
This GWAS identified SNPs associated with MS-AEs in women treated with AIs and with a gene (TCL1A) which, in turn, was related to a cytokine (IL17). These findings provide a focus for further research to identify patients at risk for MS-AEs and to explore the mechanisms for these adverse events. |
|---|---|
| AbstractList | We performed a case-control genome-wide association study (GWAS) to identify single nucleotide polymorphisms (SNPs) associated with musculoskeletal adverse events (MS-AEs) in women treated with aromatase inhibitors (AIs) for early breast cancer.PURPOSEWe performed a case-control genome-wide association study (GWAS) to identify single nucleotide polymorphisms (SNPs) associated with musculoskeletal adverse events (MS-AEs) in women treated with aromatase inhibitors (AIs) for early breast cancer.A nested case-control design was used to select patients enrolled onto the MA.27 phase III trial comparing anastrozole with exemestane. Cases were matched to two controls and were defined as patients with grade 3 or 4 MS-AEs (according to the National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0) or those who discontinued treatment for any grade of MS-AE within the first 2 years. Genotyping was performed with the Illumina Human610-Quad BeadChip.PATIENTS AND METHODSA nested case-control design was used to select patients enrolled onto the MA.27 phase III trial comparing anastrozole with exemestane. Cases were matched to two controls and were defined as patients with grade 3 or 4 MS-AEs (according to the National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0) or those who discontinued treatment for any grade of MS-AE within the first 2 years. Genotyping was performed with the Illumina Human610-Quad BeadChip.The GWAS included 293 cases and 585 controls. A total of 551,358 SNPs were analyzed, followed by imputation and fine mapping of a region of interest on chromosome 14. Four SNPs on chromosome 14 had the lowest P values (2.23E-06 to 6.67E-07). T-cell leukemia 1A (TCL1A) was the gene closest (926-7000 bp) to the four SNPs. Functional genomic studies revealed that one of these SNPs (rs11849538) created an estrogen response element and that TCL1A expression was estrogen dependent, was associated with the variant SNP genotypes in estradiol-treated lymphoblastoid cells transfected with estrogen receptor alpha and was directly related to interleukin 17 receptor A (IL17RA) expression.RESULTSThe GWAS included 293 cases and 585 controls. A total of 551,358 SNPs were analyzed, followed by imputation and fine mapping of a region of interest on chromosome 14. Four SNPs on chromosome 14 had the lowest P values (2.23E-06 to 6.67E-07). T-cell leukemia 1A (TCL1A) was the gene closest (926-7000 bp) to the four SNPs. Functional genomic studies revealed that one of these SNPs (rs11849538) created an estrogen response element and that TCL1A expression was estrogen dependent, was associated with the variant SNP genotypes in estradiol-treated lymphoblastoid cells transfected with estrogen receptor alpha and was directly related to interleukin 17 receptor A (IL17RA) expression.This GWAS identified SNPs associated with MS-AEs in women treated with AIs and with a gene (TCL1A) which, in turn, was related to a cytokine (IL17). These findings provide a focus for further research to identify patients at risk for MS-AEs and to explore the mechanisms for these adverse events.CONCLUSIONThis GWAS identified SNPs associated with MS-AEs in women treated with AIs and with a gene (TCL1A) which, in turn, was related to a cytokine (IL17). These findings provide a focus for further research to identify patients at risk for MS-AEs and to explore the mechanisms for these adverse events. We performed a case-control genome-wide association study (GWAS) to identify single nucleotide polymorphisms (SNPs) associated with musculoskeletal adverse events (MS-AEs) in women treated with aromatase inhibitors (AIs) for early breast cancer. A nested case-control design was used to select patients enrolled onto the MA.27 phase III trial comparing anastrozole with exemestane. Cases were matched to two controls and were defined as patients with grade 3 or 4 MS-AEs (according to the National Cancer Institute's Common Terminology Criteria for Adverse Events v3.0) or those who discontinued treatment for any grade of MS-AE within the first 2 years. Genotyping was performed with the Illumina Human610-Quad BeadChip. The GWAS included 293 cases and 585 controls. A total of 551,358 SNPs were analyzed, followed by imputation and fine mapping of a region of interest on chromosome 14. Four SNPs on chromosome 14 had the lowest P values (2.23E-06 to 6.67E-07). T-cell leukemia 1A (TCL1A) was the gene closest (926-7000 bp) to the four SNPs. Functional genomic studies revealed that one of these SNPs (rs11849538) created an estrogen response element and that TCL1A expression was estrogen dependent, was associated with the variant SNP genotypes in estradiol-treated lymphoblastoid cells transfected with estrogen receptor alpha and was directly related to interleukin 17 receptor A (IL17RA) expression. This GWAS identified SNPs associated with MS-AEs in women treated with AIs and with a gene (TCL1A) which, in turn, was related to a cytokine (IL17). These findings provide a focus for further research to identify patients at risk for MS-AEs and to explore the mechanisms for these adverse events. |
| Author | Liu, Mohan Chapman, Judy-Anne W Pritchard, Kathleen I Ingle, James N Batzler, Anthony Weinshilboum, Richard M Rohrer, Daniel C Wang, Liewei Goetz, Matthew P Jenkins, Gregory D Kubo, Michiaki Stearns, Vered Nakamura, Yusuke Pater, Joseph Flockhart, David A Schaid, Daniel J Mushiroda, Taisei Ellis, Matthew J Shepherd, Lois Goss, Paul E |
| Author_xml | – sequence: 1 givenname: James N surname: Ingle fullname: Ingle, James N email: ingle.james@mayo.edu organization: Mayo Clinic, Rochester, MN 55905, USA. ingle.james@mayo.edu – sequence: 2 givenname: Daniel J surname: Schaid fullname: Schaid, Daniel J – sequence: 3 givenname: Paul E surname: Goss fullname: Goss, Paul E – sequence: 4 givenname: Mohan surname: Liu fullname: Liu, Mohan – sequence: 5 givenname: Taisei surname: Mushiroda fullname: Mushiroda, Taisei – sequence: 6 givenname: Judy-Anne W surname: Chapman fullname: Chapman, Judy-Anne W – sequence: 7 givenname: Michiaki surname: Kubo fullname: Kubo, Michiaki – sequence: 8 givenname: Gregory D surname: Jenkins fullname: Jenkins, Gregory D – sequence: 9 givenname: Anthony surname: Batzler fullname: Batzler, Anthony – sequence: 10 givenname: Lois surname: Shepherd fullname: Shepherd, Lois – sequence: 11 givenname: Joseph surname: Pater fullname: Pater, Joseph – sequence: 12 givenname: Liewei surname: Wang fullname: Wang, Liewei – sequence: 13 givenname: Matthew J surname: Ellis fullname: Ellis, Matthew J – sequence: 14 givenname: Vered surname: Stearns fullname: Stearns, Vered – sequence: 15 givenname: Daniel C surname: Rohrer fullname: Rohrer, Daniel C – sequence: 16 givenname: Matthew P surname: Goetz fullname: Goetz, Matthew P – sequence: 17 givenname: Kathleen I surname: Pritchard fullname: Pritchard, Kathleen I – sequence: 18 givenname: David A surname: Flockhart fullname: Flockhart, David A – sequence: 19 givenname: Yusuke surname: Nakamura fullname: Nakamura, Yusuke – sequence: 20 givenname: Richard M surname: Weinshilboum fullname: Weinshilboum, Richard M |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20876420$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkL1PwzAQxS0Eoh-wMyFvTCm2E8fJiCoooEpdYI6uzrkYErvETitG_nNSUSSWe_dOPz093YScOu-QkCvOZlwwdvs8X80EG5woZpLl2QkZcylUopSUp__2EZmE8M4Yz4pUnpORYIXKM8HG5HuBzreY7G2NFELw2kK03gUKrqamd_rgoKGbA2c1DbGvLQbqDW37oPvGhw9sMA4I1DvsAlLcoYuBWkf3Q7SjHWq0O-s2FDrfQoSBse7Nrm30XbggZwaagJdHnZLXh_uX-WOyXC2e5nfLREspYyJYztKhtc4LkRbA0tJwPkwFyIrSMAVyuIjSoC40ZHnNjTEcVAmZKjljYkpufnO3nf_sMcSqtUFj04BD34dK5SLLSy7Sgbw-kv26xbradraF7qv6-5r4AUR8c0Q |
| CitedBy_id | crossref_primary_10_1016_S1470_2045_11_70345_X crossref_primary_10_1111_bcp_13130 crossref_primary_10_1158_1078_0432_CCR_12_2618 crossref_primary_10_4137_BCBCR_S6234 crossref_primary_10_1002_gepi_20632 crossref_primary_10_2217_fon_13_57 crossref_primary_10_1188_12_CJON_260_266 crossref_primary_10_1517_14656566_2012_687721 crossref_primary_10_1016_j_clgc_2016_05_011 crossref_primary_10_1111_bcp_12166 crossref_primary_10_1002_cncr_27465 crossref_primary_10_1124_mol_117_108340 crossref_primary_10_1210_me_2012_1397 crossref_primary_10_1016_j_etap_2014_10_022 crossref_primary_10_1186_bcr3137 crossref_primary_10_1200_JCO_2011_38_0261 crossref_primary_10_1016_j_jand_2017_09_024 crossref_primary_10_3109_10408363_2015_1075469 crossref_primary_10_1186_gm391 crossref_primary_10_1080_17425255_2017_1234605 crossref_primary_10_1146_annurev_pharmtox_010611_134520 crossref_primary_10_1371_journal_pone_0118020 crossref_primary_10_1007_s40142_013_0022_6 crossref_primary_10_1016_j_mito_2021_02_005 crossref_primary_10_1097_FPC_0000000000000522 crossref_primary_10_1097_HP_0000000000000013 crossref_primary_10_1097_FPC_0000000000000241 crossref_primary_10_1007_s10549_014_2873_2 crossref_primary_10_1158_1078_0432_CCR_11_1938 crossref_primary_10_1016_j_breast_2017_01_004 crossref_primary_10_1016_j_steroids_2015_07_009 crossref_primary_10_1007_s12609_012_0088_2 crossref_primary_10_1038_jhg_2013_35 crossref_primary_10_1016_S0959_8049_12_70063_1 crossref_primary_10_3389_fgene_2021_662734 crossref_primary_10_1097_FPC_0000000000000092 crossref_primary_10_1038_s41523_017_0036_4 crossref_primary_10_1007_s10549_013_2638_3 crossref_primary_10_1038_tpj_2016_60 crossref_primary_10_1186_s12967_016_0778_z crossref_primary_10_1016_j_breast_2013_02_015 crossref_primary_10_2217_PGS_15_54 crossref_primary_10_1016_j_breast_2016_02_010 crossref_primary_10_1016_j_ctrv_2018_07_014 crossref_primary_10_3389_fphar_2018_00158 crossref_primary_10_1007_s11912_021_01055_5 crossref_primary_10_1210_me_2014_1147 crossref_primary_10_2217_pgs_10_217 crossref_primary_10_1007_s10549_015_3608_8 crossref_primary_10_1093_hmg_ddr583 crossref_primary_10_1007_s10269_012_2180_7 crossref_primary_10_1158_0008_5472_CAN_16_1371 crossref_primary_10_1080_19466315_2013_873000 crossref_primary_10_1002_cpt_2349 crossref_primary_10_1002_cpt_915 crossref_primary_10_1186_1471_2105_15_S10_P29 crossref_primary_10_1200_JCO_2014_57_9235 crossref_primary_10_2217_pgs_14_170 crossref_primary_10_1177_1534735420980811 crossref_primary_10_1016_j_breast_2013_07_035 crossref_primary_10_1177_1099800419895114 crossref_primary_10_1093_bib_bbaa292 crossref_primary_10_1155_2022_8901326 crossref_primary_10_2337_db14_0609 crossref_primary_10_1158_2159_8290_CD_13_0251 crossref_primary_10_1371_journal_pone_0048416 crossref_primary_10_1186_s13058_015_0599_7 crossref_primary_10_2217_pgs_2019_0191 crossref_primary_10_1200_JCO_2014_57_6926 crossref_primary_10_1124_jpet_118_247718 crossref_primary_10_1038_tpj_2012_32 crossref_primary_10_1158_1078_0432_CCR_13_2755 crossref_primary_10_1016_j_clbc_2018_11_009 crossref_primary_10_1002_cpt_2311 crossref_primary_10_1634_theoncologist_2011_0202 crossref_primary_10_1093_hmg_ddw301 crossref_primary_10_1007_s10549_013_2792_7 crossref_primary_10_2217_pgs_2016_0205 crossref_primary_10_3390_metabo15030153 crossref_primary_10_2217_pgs_11_115 crossref_primary_10_1186_s13073_016_0382_0 crossref_primary_10_3390_cancers13215455 crossref_primary_10_1007_s12038_018_9817_7 crossref_primary_10_1111_ahg_12117 crossref_primary_10_2217_pgs_15_131 crossref_primary_10_1007_s10549_021_06448_5 crossref_primary_10_1089_dna_2011_1292 crossref_primary_10_1126_scitranslmed_3003471 crossref_primary_10_1200_JCO_2010_31_2926 crossref_primary_10_2217_pgs_12_37 crossref_primary_10_1093_jnci_djr533 crossref_primary_10_1007_s10549_011_1351_3 crossref_primary_10_1016_j_pharmthera_2013_03_001 crossref_primary_10_5306_wjco_v5_i5_1088 crossref_primary_10_1586_erm_13_26 crossref_primary_10_1371_journal_pone_0247989 crossref_primary_10_1146_annurev_genom_090413_025419 crossref_primary_10_1056_NEJMra1010600 crossref_primary_10_2217_pgs_11_121 crossref_primary_10_1007_s00520_020_05473_2 crossref_primary_10_1007_s10549_015_3378_3 crossref_primary_10_1016_S1470_2045_17_30698_8 crossref_primary_10_1016_j_cct_2024_107780 crossref_primary_10_1210_clinem_dgaa536 crossref_primary_10_1007_s12609_010_0018_0 crossref_primary_10_1016_j_ctrv_2011_08_003 crossref_primary_10_1007_s10549_013_2427_z crossref_primary_10_1515_CCLM_2011_715 crossref_primary_10_1111_cas_13463 crossref_primary_10_2217_pgs_12_28 crossref_primary_10_1093_annonc_mds290 crossref_primary_10_1158_2159_8290_CD_13_0038 crossref_primary_10_1007_s00520_022_07243_8 crossref_primary_10_1371_journal_pone_0133964 crossref_primary_10_1007_s10549_020_05777_1 crossref_primary_10_1016_j_clbc_2017_10_009 crossref_primary_10_1158_1078_0432_CCR_23_2137 crossref_primary_10_1186_1471_2164_15_93 crossref_primary_10_1007_s10549_013_2504_3 crossref_primary_10_2217_pgs_2016_0141 crossref_primary_10_1007_s10549_019_05270_4 crossref_primary_10_1517_17425255_2015_1053460 crossref_primary_10_1007_s00520_025_09183_5 crossref_primary_10_1016_j_molonc_2012_02_003 crossref_primary_10_1007_s10549_011_1578_z crossref_primary_10_1093_pm_pny067 crossref_primary_10_2147_PGPM_S308531 crossref_primary_10_2217_pgs_13_226 crossref_primary_10_1186_bcr2746 crossref_primary_10_1016_j_cmonc_2012_02_005 crossref_primary_10_1016_j_tig_2012_06_008 crossref_primary_10_1124_dmd_119_087312 crossref_primary_10_1186_s13058_024_01861_2 crossref_primary_10_1007_s10549_012_2010_z crossref_primary_10_1080_17425255_2016_1196189 crossref_primary_10_1097_MD_0000000000020085 crossref_primary_10_1038_nrg3352 crossref_primary_10_1007_s11306_016_1066_x crossref_primary_10_1210_me_2015_1267 crossref_primary_10_1371_journal_pone_0086263 crossref_primary_10_2217_pgs_12_44 crossref_primary_10_1007_s00439_012_1221_z crossref_primary_10_1007_s11136_014_0656_1 crossref_primary_10_1186_s12863_016_0348_7 crossref_primary_10_2217_pgs_2017_0006 crossref_primary_10_1016_j_ejca_2015_12_013 crossref_primary_10_1097_FPC_0b013e32834dd7e2 crossref_primary_10_1097_GME_0000000000001545 crossref_primary_10_1016_j_breast_2019_10_008 crossref_primary_10_1016_j_yamp_2018_06_007 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1200/JCO.2010.28.5064 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1527-7755 |
| ExternalDocumentID | 20876420 |
| Genre | Comparative Study Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIGMS NIH HHS grantid: U01 GM061388 – fundername: NIGMS NIH HHS grantid: U01GM63173 – fundername: NCI NIH HHS grantid: P50CA116201 – fundername: NCI NIH HHS grantid: P50 CA116201 – fundername: NCI NIH HHS grantid: U10CA77202 – fundername: NCI NIH HHS grantid: U10 CA077202 – fundername: NIGMS NIH HHS grantid: U01GM61388 |
| GroupedDBID | --- .55 0R~ 18M 2WC 34G 39C 3O- 4.4 53G 5GY 5RE 8F7 AARDX AAWTL AAYEP AAYOK ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AFFNX AI. AIAGR ALMA_UNASSIGNED_HOLDINGS BAWUL C45 CGR CS3 CUY CVF DIK EBS ECM EIF EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 KQ8 L7B LSO MJL N4W N9A NPM O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN TEORI TR2 TWZ UDS VH1 VVN WH7 X7M YCJ YFH YQY 7X8 ABBLC |
| ID | FETCH-LOGICAL-c555t-20603876c68238a039f110397ae089f07a59f129fec8ca46d1fff1a79a4791002 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 173 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000283585200019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1527-7755 |
| IngestDate | Sat Oct 11 07:09:12 EDT 2025 Thu Apr 03 04:55:12 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 31 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c555t-20603876c68238a039f110397ae089f07a59f129fec8ca46d1fff1a79a4791002 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2010.28.5064?role=tab |
| PMID | 20876420 |
| PQID | 762469123 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_762469123 pubmed_primary_20876420 |
| PublicationCentury | 2000 |
| PublicationDate | 2010-11-01 |
| PublicationDateYYYYMMDD | 2010-11-01 |
| PublicationDate_xml | – month: 11 year: 2010 text: 2010-11-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of clinical oncology |
| PublicationTitleAlternate | J Clin Oncol |
| PublicationYear | 2010 |
| References | 17200148 - J Clin Oncol. 2007 Feb 10;25(5):486-92 17761973 - J Clin Oncol. 2007 Sep 1;25(25):3877-83 17194218 - PLoS Genet. 2006 Dec;2(12):e190 11607815 - Oncogene. 2001 Sep 10;20(40):5638-43 2273353 - J Epidemiol Community Health. 1990 Sep;44(3):179-86 11315092 - Biometrics. 1999 Dec;55(4):997-1004 17701901 - Am J Hum Genet. 2007 Sep;81(3):559-75 18332472 - J Clin Oncol. 2008 Apr 20;26(12):1965-71 18596976 - PLoS One. 2008;3(7):e2551 17922185 - Breast Cancer Res Treat. 2008 Sep;111(2):365-72 17563395 - J Clin Oncol. 2007 Jul 1;25(19):2664-70 19630580 - Annu Rev Med. 2009;60:443-56 16145047 - J Natl Cancer Inst. 2005 Sep 7;97(17):1262-71 18852203 - Hum Mol Genet. 2008 Oct 15;17(R2):R143-50 16084253 - Lancet. 2005 Aug 6-12;366(9484):455-62 18180462 - J Clin Oncol. 2008 Feb 1;26(4):556-62 20876427 - J Clin Oncol. 2010 Nov 1;28(31):4665-6 18349094 - JAMA. 2008 Mar 19;299(11):1335-44 16760270 - Ann Oncol. 2006 Jun;17 Suppl 7:vii10-4 19710487 - N Engl J Med. 2009 Aug 27;361(9):888-98 15545664 - J Clin Oncol. 2005 Jan 20;23(3):619-29 17307102 - Lancet. 2007 Feb 17;369(9561):559-70 15713944 - N Engl J Med. 2005 Mar 17;352(11):1071-80 16862161 - Nat Genet. 2006 Aug;38(8):904-9 19715440 - Annu Rev Genomics Hum Genet. 2009;10:387-406 18083636 - Lancet Oncol. 2008 Jan;9(1):45-53 18208329 - PLoS Genet. 2008 Jan;4(1):e4 17360849 - FASEB J. 2007 Aug;21(10):2273-84 |
| References_xml | – reference: 2273353 - J Epidemiol Community Health. 1990 Sep;44(3):179-86 – reference: 11315092 - Biometrics. 1999 Dec;55(4):997-1004 – reference: 17563395 - J Clin Oncol. 2007 Jul 1;25(19):2664-70 – reference: 16145047 - J Natl Cancer Inst. 2005 Sep 7;97(17):1262-71 – reference: 18596976 - PLoS One. 2008;3(7):e2551 – reference: 15545664 - J Clin Oncol. 2005 Jan 20;23(3):619-29 – reference: 17922185 - Breast Cancer Res Treat. 2008 Sep;111(2):365-72 – reference: 18852203 - Hum Mol Genet. 2008 Oct 15;17(R2):R143-50 – reference: 16760270 - Ann Oncol. 2006 Jun;17 Suppl 7:vii10-4 – reference: 17307102 - Lancet. 2007 Feb 17;369(9561):559-70 – reference: 18349094 - JAMA. 2008 Mar 19;299(11):1335-44 – reference: 18180462 - J Clin Oncol. 2008 Feb 1;26(4):556-62 – reference: 18332472 - J Clin Oncol. 2008 Apr 20;26(12):1965-71 – reference: 20876427 - J Clin Oncol. 2010 Nov 1;28(31):4665-6 – reference: 19710487 - N Engl J Med. 2009 Aug 27;361(9):888-98 – reference: 17761973 - J Clin Oncol. 2007 Sep 1;25(25):3877-83 – reference: 15713944 - N Engl J Med. 2005 Mar 17;352(11):1071-80 – reference: 18208329 - PLoS Genet. 2008 Jan;4(1):e4 – reference: 18083636 - Lancet Oncol. 2008 Jan;9(1):45-53 – reference: 17360849 - FASEB J. 2007 Aug;21(10):2273-84 – reference: 19715440 - Annu Rev Genomics Hum Genet. 2009;10:387-406 – reference: 17200148 - J Clin Oncol. 2007 Feb 10;25(5):486-92 – reference: 11607815 - Oncogene. 2001 Sep 10;20(40):5638-43 – reference: 16084253 - Lancet. 2005 Aug 6-12;366(9484):455-62 – reference: 17194218 - PLoS Genet. 2006 Dec;2(12):e190 – reference: 16862161 - Nat Genet. 2006 Aug;38(8):904-9 – reference: 17701901 - Am J Hum Genet. 2007 Sep;81(3):559-75 – reference: 19630580 - Annu Rev Med. 2009;60:443-56 |
| SSID | ssj0014835 |
| Score | 2.4394574 |
| Snippet | We performed a case-control genome-wide association study (GWAS) to identify single nucleotide polymorphisms (SNPs) associated with musculoskeletal adverse... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 4674 |
| SubjectTerms | Aged Aged, 80 and over Androstadienes - adverse effects Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Aromatase Inhibitors - administration & dosage Aromatase Inhibitors - adverse effects Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - pathology Case-Control Studies Chromosome Mapping Chromosomes, Human, Pair 14 Clinical Trials, Phase III as Topic Estrogens - metabolism Female Gene Expression Regulation, Neoplastic Genome-Wide Association Study Genotype Humans Logistic Models Middle Aged Musculoskeletal System - drug effects Neoplasm Staging Nitriles - adverse effects Polymorphism, Single Nucleotide Postmenopause Proto-Oncogene Proteins - genetics Randomized Controlled Trials as Topic Receptors, Interleukin-17 - metabolism Retrospective Studies Severity of Illness Index Triazoles - adverse effects |
| Title | Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/20876420 https://www.proquest.com/docview/762469123 |
| Volume | 28 |
| WOSCitedRecordID | wos000283585200019&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1NT9tAEF0VqCou0KYFArSaQ5UTLv5Ye70nhBAUIZHmQKXcorG9KywUO2QTEEf-OTO2aU6oBy4-2LJkaXZmnvfNvifEzzxUgY2KxNMm0J4sCt9DzCivkH8GWAA8as0m1HCYjsd61M3muG6s8rUmNoW6qHPeIz-mpKU_OaqzJ7N7j02jmFztHDTWxEZESIbzUo1XJIJMG39NNm4lEBnHHUtJ6-L46uxPO9YVpr9Ysu1tfNn0mYvtd37hZ7HVAUw4bVfEF_HBVD3x6bqj0HtiMGrFqp-O4GZ19sodwQBGKxnrp6_i-bep6qnxHsvCAK6i6ACrArgfttuIwDKv0zIH144kQm1huuT51trdUVMjdA_Its_OQCMX5aCsoFF-ACq3puQtDcB5TdiZWio9vC2zkk2Avom_F-c3Z5deZ9jg5XEcLyjjEmbDkzxJCQmgH2kbMNWs0Piptr7CmO6E2po8zVEmRWCtDVBplEqzFuyOWK_qyuwJkBkGykpro8yXmY5Q8hlgkyUKMSKQ1hfwGoQJJQSzHFiZeukm_8LQF7ttICezVrhjErL-ngz9_f-_fCA2mzmB5tThodiwVAzMd_Exf1iUbv6jWWh0HY6uXwDzit9q |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Genome-wide+associations+and+functional+genomic+studies+of+musculoskeletal+adverse+events+in+women+receiving+aromatase+inhibitors&rft.jtitle=Journal+of+clinical+oncology&rft.au=Ingle%2C+James+N&rft.au=Schaid%2C+Daniel+J&rft.au=Goss%2C+Paul+E&rft.au=Liu%2C+Mohan&rft.date=2010-11-01&rft.eissn=1527-7755&rft.volume=28&rft.issue=31&rft.spage=4674&rft_id=info:doi/10.1200%2FJCO.2010.28.5064&rft_id=info%3Apmid%2F20876420&rft_id=info%3Apmid%2F20876420&rft.externalDocID=20876420 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-7755&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-7755&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-7755&client=summon |